Pathology Under the Microscope: From Slides to Systems

Pathology has long been defined by three familiar images: a microscope, a glass slide, and a specialist interpreting what they see.

That model still exists, but in 2026 and beyond, it’s no longer where the pathology field is heading.

Today, pathology is evolving into a data-driven, technology-enabled system shaped by digital imaging, automation, and artificial intelligence. The shift isn’t just about new tools; it’s about how pathology operates, how decisions are made, and how value is created across healthcare.

In its recent report, The Future of Pathology: Automated Platforms, Digital Imaging, and Market Dynamics, 3rd Edition, Kalorama Information explores the implications of this shift and highlights the most significant opportunities across the $9.5 billion global IVD pathology market, including PAP tests, ISH, IHC, HPV, CTC, flow cytometry, and digital pathology.

Digital Pathology Is Becoming the Foundation

One of the clearest shifts in Kalorama’s report is the move away from glass slides as the center of the workflow.

Digital pathology, converting slides into high-resolution images, enables something much larger:

• Remote consultation and collaboration
• Faster turnaround times
• Standardized and reproducible interpretation

More importantly, it allows pathology data to be stored, shared, and integrated with other systems, including hospital records and molecular data.

This transition turns pathology into a scalable, connected workflow rather than a localized, manual process.

“Digital pathology is no longer just a technology upgrade, it’s the infrastructure that supports everything else, from AI to precision medicine,” said Dr. Melissa Dueck, Kalorama’s Senior Healthcare Market Specialist and co-author of the report.

AI Is About Efficiency and Consistency

Artificial intelligence is increasingly being used to support pathologists, particularly in high-volume or repetitive tasks.

In practice, AI tools help by:

• Highlighting subtle patterns in images
• Pre-screening slides
• Quantifying biomarkers and features

These capabilities reduce variability between readers and improve consistency across cases.

Likewise, AI addresses practical challenges. As testing volumes rise and pathologist shortages persist, automation of routine tasks allows specialists to focus on complex cases and clinical decision-making.

“AI is less about replacing pathologists and more about enabling them to work faster, more consistently, and at greater scale,” said Dr. Dueck.

Precision Medicine Is Driving the Shift in Testing

Another major theme in the report is the increasing complexity of pathology testing, particularly in oncology.

The field is moving:

• From single-marker tests to multiplex and multi-analyte assays
• From qualitative assessments to quantitative biomarker measurement
• From standalone analysis to integration with molecular and genomic data

Technologies like immunohistochemistry (IHC), in situ hybridization (ISH), and next-generation sequencing are becoming more integrated into routine workflows, especially for cancer diagnostics.

Pathology is no longer just about identifying disease, but also about guiding treatment decisions and monitoring outcomes.

“Growth in pathology is increasingly tied to clinical value, not volume,” said Dr. Dueck. “Tests that support therapy selection and personalized care have become central.”

Automation Is Reshaping the Lab

Rising test volumes and workforce constraints are pushing laboratories toward greater automation.

This includes:

• Automated staining and sample preparation
• Integrated, end-to-end workflow systems
• Standardized processes that reduce variability

Automation improves speed and reproducibility while helping labs manage increasing demand without proportional increases in staff.

Notably, many of these systems are now being designed as part of larger, connected workflows rather than standalone instruments.

“Automation is not just about efficiency gains, but it has become essential for maintaining quality and throughput in modern pathology labs,” said Dr. Dueck.

A Market Divided Between Stability and Innovation

The report highlights a clear divide within pathology.

Some segments remain stable and mature:

• Traditional tissue stains
• Cytology and Pap testing
• Routine histology workflows

Others are advancing more rapidly:

• Digital pathology
• AI-enabled image analysis
• Molecular and biomarker-driven testing

This creates a dual reality in which pathology remains rooted in high-volume, low-growth services while also expanding into high-value, technology-driven applications.

“Organizations must balance operational efficiency in core services with targeted investment in emerging technologies,” said Dr. Dueck.

Global Disparities Create Long-Term Opportunity

While advanced technologies are transforming pathology in developed markets, the report also highlights uneven global access.

In many regions:

• Screening rates remain low
• Laboratory infrastructure is limited
• Access to specialists is constrained

At the same time, these areas represent a significant unmet need, particularly for cancer diagnostics.

“Expanding access through scalable technologies, improved workflows, and broader infrastructure remains a key opportunity for growth,” said Dr. Dueck.

What It Means

Pathology is evolving from a primarily manual, interpretive discipline into a more standardized, data-driven component of healthcare.

The key forces driving this shift are clear:

• Digitization of slides and workflows
• Integration of AI into routine processes
• Expansion of molecular and precision testing
• Growing reliance on automation to manage demand

Together, these changes are redefining how pathology contributes to diagnosis, treatment selection, and patient care.

The microscope remains central, but it is now part of a much larger system. And increasingly, that system is where the future of pathology will be defined.

Pathology has long been defined by three familiar images: a microscope, a glass slide, and a specialist interpreting what they see.

That model still exists, but in 2026 and beyond, it’s no longer where the pathology field is heading.

Today, pathology is evolving into a data-driven, technology-enabled system shaped by digital imaging, automation, and artificial intelligence. The shift isn’t just about new tools; it’s about how pathology operates, how decisions are made, and how value is created across healthcare.

In its recent report, The Future of Pathology: Automated Platforms, Digital Imaging, and Market Dynamics, 3rd Edition, Kalorama Information explores the implications of this shift and highlights the most significant opportunities across the $9.5 billion global IVD pathology market, including PAP tests, ISH, IHC, HPV, CTC, flow cytometry, and digital pathology.

Digital Pathology Is Becoming the Foundation

One of the clearest shifts in Kalorama’s report is the move away from glass slides as the center of the workflow.

Digital pathology, converting slides into high-resolution images, enables something much larger:

• Remote consultation and collaboration
• Faster turnaround times
• Standardized and reproducible interpretation

More importantly, it allows pathology data to be stored, shared, and integrated with other systems, including hospital records and molecular data.

This transition turns pathology into a scalable, connected workflow rather than a localized, manual process.

“Digital pathology is no longer just a technology upgrade; it’s the infrastructure that supports everything else, from AI to precision medicine,” said Dr. Melissa Dueck, Kalorama’s Senior Healthcare Market Specialist and co-author of the report.

AI Is About Efficiency and Consistency

Artificial intelligence is increasingly being used to support pathologists, particularly in high-volume or repetitive tasks.

In practice, AI tools help by:

• Highlighting subtle patterns in images
• Pre-screening slides
• Quantifying biomarkers and features

These capabilities reduce variability between readers and improve consistency across cases.

Likewise, AI addresses practical challenges. As testing volumes rise and pathologist shortages persist, automation of routine tasks allows specialists to focus on complex cases and clinical decision-making.

“AI is less about replacing pathologists and more about enabling them to work faster, more consistently, and at greater scale,” said Dr. Dueck.

Precision Medicine Is Driving the Shift in Testing

Another major theme in the report is the increasing complexity of pathology testing, particularly in oncology.

The field is moving:

• From single-marker tests to multiplex and multi-analyte assays
• From qualitative assessments to quantitative biomarker measurement
• From standalone analysis to integration with molecular and genomic data

Technologies like immunohistochemistry (IHC), in situ hybridization (ISH), and next-generation sequencing are becoming more integrated into routine workflows, especially for cancer diagnostics.

Pathology is no longer just about identifying disease, but also about guiding treatment decisions and monitoring outcomes.

“Growth in pathology is increasingly tied to clinical value, not volume,” said Dr. Dueck. “Tests that support therapy selection and personalized care have become central.”

Automation Is Reshaping the Lab

Rising test volumes and workforce constraints are pushing laboratories toward greater automation.

This includes:

• Automated staining and sample preparation
• Integrated, end-to-end workflow systems
• Standardized processes that reduce variability

Automation improves speed and reproducibility while helping labs manage increasing demand without proportional increases in staff.

Notably, many of these systems are now being designed as part of larger, connected workflows rather than standalone instruments.

“Automation is not just about efficiency gains, but it has become essential for maintaining quality and throughput in modern pathology labs,” said Dr. Dueck.

A Market Divided Between Stability and Innovation

The report highlights a clear divide within pathology.

Some segments remain stable and mature:

• Traditional tissue stains
• Cytology and Pap testing
• Routine histology workflows

Others are advancing more rapidly:

• Digital pathology
• AI-enabled image analysis
• Molecular and biomarker-driven testing

This creates a dual reality in which pathology remains rooted in high-volume, low-growth services while also expanding into high-value, technology-driven applications.

“Organizations must balance operational efficiency in core services with targeted investment in emerging technologies,” said Dr. Dueck.

Global Disparities Create Long-Term Opportunity

While advanced technologies are transforming pathology in developed markets, the report also highlights uneven global access.

In many regions:

• Screening rates remain low
• Laboratory infrastructure is limited
• Access to specialists is constrained

At the same time, these areas represent significant unmet need, particularly for cancer diagnostics.

“Expanding access through scalable technologies, improved workflows, and broader infrastructure remains a key opportunity for growth,” said Dr. Dueck.

What It Means

Pathology is evolving from a primarily manual, interpretive discipline into a more standardized, data-driven component of healthcare.

The key forces driving this shift are clear:

• Digitization of slides and workflows
• Integration of AI into routine processes
• Expansion of molecular and precision testing
• Growing reliance on automation to manage demand

Together, these changes are redefining how pathology contributes to diagnosis, treatment selection, and patient care.

The microscope remains central, but it is now part of a much larger system. And increasingly, that system is where the future of pathology will be defined.